Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yaolin Wang

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Cancer Science|May 9, 2023
D-1553: A novel KRAS<sup>G12C</sup> inhibitor with potent and selective cellular and in vivo antitumor activityZhe Shi, Jifang Weng, Haotao Niu, et al.
British Journal of Cancer|December 4, 2025
Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancerNoboru Yamamoto, Dong Yan, Vinod Ganju, et al.
Molecular Cancer Therapeutics|July 29, 2010
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitorDavid Parry, Timothy Guzi, Frances Shanahan, et al.
Molecular Cancer Therapeutics|August 12, 2005
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibodyYan Wang, Judith Hailey, Denise Williams, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 22, 2023
D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS<sup>G12C</sup> in Patients With NSCLC: Phase 1 Study ResultsZiming Li, Zhengbo Song, Yanqiu Zhao, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 InhibitorsStéphane L Bogen, Weidong Pan, Craig R Gibeau, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2007
Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2Kamil Paruch, Michael P Dwyer, Carmen Alvarez, et al.
Plos One|October 8, 2014
MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosisRobert N Booher, Harold Hatch, Brian M Dolinski, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent KinasesKamil Paruch, Michael P Dwyer, Carmen Alvarez, et al.
Signal Transduction and Targeted Therapy|June 16, 2025
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutationDan-Yun Ruan, Hao-Xiang Wu, Ye Xu, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Cancer Science|May 9, 2023
D-1553: A novel KRAS<sup>G12C</sup> inhibitor with potent and selective cellular and in vivo antitumor activityZhe Shi, Jifang Weng, Haotao Niu, et al.
British Journal of Cancer|December 4, 2025
Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancerNoboru Yamamoto, Dong Yan, Vinod Ganju, et al.
Molecular Cancer Therapeutics|July 29, 2010
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitorDavid Parry, Timothy Guzi, Frances Shanahan, et al.
Molecular Cancer Therapeutics|August 12, 2005
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibodyYan Wang, Judith Hailey, Denise Williams, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 22, 2023
D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS<sup>G12C</sup> in Patients With NSCLC: Phase 1 Study ResultsZiming Li, Zhengbo Song, Yanqiu Zhao, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 InhibitorsStéphane L Bogen, Weidong Pan, Craig R Gibeau, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2007
Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2Kamil Paruch, Michael P Dwyer, Carmen Alvarez, et al.
Plos One|October 8, 2014
MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosisRobert N Booher, Harold Hatch, Brian M Dolinski, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent KinasesKamil Paruch, Michael P Dwyer, Carmen Alvarez, et al.
Signal Transduction and Targeted Therapy|June 16, 2025
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutationDan-Yun Ruan, Hao-Xiang Wu, Ye Xu, et al.
Pageof 7